Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting NLRP3 signaling by a novel-designed sulfonylurea compound for inhibition of microglial inflammation
Changwen Zhang, Ayyiliath M. Sajith, Xiaotian Xu, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 58, pp. 116645-116645
Open Access | Times Cited: 16

Showing 16 citing articles:

Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress
Zhipei Sang, Keren Wang, Jianghong Dong, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114464-114464
Closed Access | Times Cited: 80
Mechanistic and therapeutic role of NLRP3 inflammasome in the pathogenesis of Alzheimer's disease
Dhanshree Jha, Erik N.T.P. Bakker, Rahul Kumar
Journal of Neurochemistry (2023)
Open Access | Times Cited: 21
Microglial TLR4/NLRP3 Inflammasome Signaling in Alzheimer’s Disease
Yunfeng Li, Xiongjin Chen, Mulan Zhou, et al.
Journal of Alzheimer s Disease (2023) Vol. 97, Iss. 1, pp. 75-88
Closed Access | Times Cited: 16
Medicinal chemistry strategies targeting NLRP3 inflammasome pathway: A recent update from 2019 to mid-2023
Meibo Duan, Lei Sun, Xinzi He, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115750-115750
Closed Access | Times Cited: 15
Review on the role of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome pathway in diabetes: mechanistic insights and therapeutic implications
Abhishek Satheesan, Janardanan Kumar, K.V. Leela, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 5, pp. 2753-2779
Closed Access | Times Cited: 6
Research progress of NLRP3 inflammasome and its inhibitors with aging diseases
Zhuo Yuan, Dongke Yu, Tingting Gou, et al.
European Journal of Pharmacology (2023) Vol. 957, pp. 175931-175931
Open Access | Times Cited: 14
Pre-clinical Studies Identifying Molecular Pathways of Neuroinflammation in Parkinson's Disease: A Systematic Review
Mobina Fathi, Kimia Vakili, Shirin Yaghoobpoor, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 18
Increased inflammasome protein expression identified in microglia from postmortem brains with schizophrenia
Ryan Gober, Julian Dallmeier, David A. Davis, et al.
Journal of Neuropathology & Experimental Neurology (2024) Vol. 83, Iss. 11, pp. 951-966
Open Access | Times Cited: 3
Ablation of Siglec-E augments brain inflammation and ischemic injury
Lexiao Li, Yu Chen, Madison N. Sluter, et al.
Journal of Neuroinflammation (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 16
NLRP3-Induced NETosis: A Potential Therapeutic Target for Ischemic Thrombotic Diseases?
Rahul Kumar, Gokul Patil, Sanjana Dayal
Cells (2023) Vol. 12, Iss. 23, pp. 2709-2709
Open Access | Times Cited: 7
Abnormal expression of miR-3653-3p, caspase 1, IL-1β in peripheral blood of schizophrenia
Xinling Zhao, Yilin Liu, Qing Long, et al.
BMC Psychiatry (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Design, synthesis and biological evaluation of tanshinone IIA derivatives as NLRP3 inflammasome inhibitors
Hao Chen, Yue Hu, Yuyun Yan, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 104, pp. 129725-129725
Closed Access | Times Cited: 1
Pharmacological targeting of microglia dynamics in Alzheimer’s disease: Preclinical and clinical evidence
Atrin Yousefizadeh, Gaia Piccioni, Amira Saidi, et al.
Pharmacological Research (2022) Vol. 184, pp. 106404-106404
Closed Access | Times Cited: 7
Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors
Tongtong Kang, Simin Sun, Huimin Wang, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 113, pp. 117927-117927
Closed Access
Targeting NLRP3 signaling with a novel sulfonylurea compound for the treatment of vascular cognitive impairment and dementia
Adnan Akif, T.T. Nguyen, Langni Liu, et al.
Research Square (Research Square) (2024)
Closed Access
The application of NLRP3 inflammasome inhibition in Alzheimers disease therapeutics: Clinical benefits, applications, current limitations, and future development
Ziyu Yan
Theoretical and Natural Science (2023) Vol. 20, Iss. 1, pp. 273-280
Open Access
Page 1

Scroll to top